Global Health Impact Forum

*Inspiring Family Offices and Foundations for Health*

United Nations Headquarters, New York

Curated by the Global Partnerships Forum with Cavendish Global and the New York Academy of Sciences

In Collaboration with The International Telecommunication Union and The UN Office for Partnerships

Monday, May 5, 2014 (UN General Assembly Hall)
Tuesday, May 6, 2014 (UN, ECOSOC Chamber)

Wednesday, May 7th, 2014 (Rockefeller University, Caspary Auditorium)

*By Invitation Only*
Global Health Impact Forum: A unique platform for pro-social family offices and foundations in support of the goals and objectives of the United Nations System. A discrete, peer-to-peer knowledge expansion and relationship building environment focused on health for a global network of over 150 leading family offices and foundations. A world-class forum for organizations actively seeking to accelerate technological innovation and health access through sustainable philanthropy, grant-making and impact investing

Principal objectives of the Forum:

1. **Champion and Share:** Provide a peer-to-peer setting for family offices and their foundations to champion and share information on sustainable philanthropy, grant-giving and impact investing projects which they are passionate about with other family offices from around the world

2. **Access Knowledge and Insight:** Help family offices and foundations identify the best scientific minds, accomplished healthcare delivery professionals, philanthropic organizations, health-policy experts and compelling private sector companies with the potential for transformational impact on disease prevention, diagnosis and treatment

3. **Partners for Action:** Action-driven platform to establish new partnerships and alliances for improved health outcomes and access; utilizing information and communication technologies (ICTs) as a key enabler

4. **Create Durable Relationships:** Establish family office collaborations and partnerships which will endure post-forum and have pro-social impact for years to come

Program highlights include:

- **Over 150 Family Investment Offices and Foundations** represented from North America, Europe, Asia, Africa and Latin America
- **Over 50 accomplished healthcare delivery professionals, health-policy experts, and philanthropic organizations** reveal specific programs driving meaningful improvements in health, health access and medical outcomes on a regional or national basis
- **Over 50 groundbreaking discoveries and innovations** by scientists and private-sector CEO's revealing groundbreaking discoveries and technology with the potential for transformational impact on disease prevention, diagnosis, treatment and medical outcomes
- **Senior partners from top-30 private equity firms and pro-social funds participating in panel discussions** (including Aisling Capital, Arsenal Capital Partners, Bridges Ventures, CityLight Capital, Easton Capital, Domain Ventures, and SV Life Sciences)
The Global Health Impact Forum is a flagship initiative of the Global Partnerships Forum (‘GPF’). The Principals of GPF have successfully organized and hosted hundreds of global and regional summits. GPF has also structured partnerships with foundations, family offices, leading multi-national corporations and governments.

Aimed at fostering Multi-Stakeholder Partnerships to address social issues by moving beyond aid to economic empowerment, and attracting foreign direct investments to create long-term sustainability, the Global Partnerships Forum, engages in the following areas to help make sustainable change happen:

a. Provide a Global Membership Network for organizations to share lessons learned, best practices and expertise.

b. Provide Strategic Advice on high-impact programs tailored to corporate missions, including: corporate governance, operational efficiency, partnerships training, and advocacy and outreach, moving from CSR to an investment model.

c. Host Global and Regional Summits that move from talk to action, centering on nation branding, multi-sectoral development and corporate leadership models.

d. Develop Regional and National Centers of Excellence and Investment Promotion Offices to attract foreign direct investment and social capital.


In addition to Chairman, Amir Dossal, the GPF Board of Directors includes:

- Howard W. Buffett, Executive Director, Howard G. Buffett Foundation
- Irene Pritzker, President, IDP Foundation
- Peter Rajsingh, Managing Partner of Castellar Partners LLC
- Ambassador Herman Schaper, Former Permanent Representative, Kingdom of the Netherlands to the United Nations
- Feike Sijbesma, CEO & Chairman, Royal DSM
The New York Academy of Sciences (the ‘Academy’) are co-organizers and co-hosts of the Forum. For nearly 200 years, since 1817, the Academy has brought together extraordinary people working at the frontiers of discovery and promoted vital links between science and society.

About the New York Academy of Sciences: The New York Academy of Sciences’ core mission is to drive innovative solutions to society’s challenges by advancing scientific research, education, and policy. It is an independent, non-government, not-for-profit founded in 1817.

The Academy achieves its mission by catalyzing novel publicprivate partnerships to address global problems. It creates and empowers expert panels to solve scientific challenges, advise governments, create and disseminate new knowledge, and inspire the next generation of scientists.

New York to the World: The Academy is a membership organization, and includes with 27 Nobel Laureates and a score of CEOs and government leaders from across the globe boasting 22,000+ members across 100 countries. It is unmatched in its commitment to the next generation, with nearly 10,000 active students and postdoctoral members.

Contributions on a Global Scale: The Academy has historically achieved and continues to make seminal contributions to the world’s grand challenges. Its earliest work is marked by many firsts that have changed the course of scientific discourse and discovery, from seminal colloquia on antibiotics to HIV-AIDs, from the SARS crisis to the swine flu (H5N1).

Today, work has taken on a new immediacy with the Academy and its partners working to DRIVE change. Twinning its ability to convene competitors and diverse sectors--academia, industry, government and civil society--with its capacity to disseminate, the Academy activates research around the toughest challenges, builds scientific capacity, and creates innovative scientific enterprise with visionary governments. Among its most significant work:

TAKING ON THE WORLD’S TOUGHEST CHALLENGES

Combating Malnutrition: The mandate for the Academy’s Sackler Institute for Nutrition Science is clear: Drive cooperative research and funding around nutrition science to solve malnutrition, a life threatening condition that affects more than a quarter of the world. In cooperation with World Health Organization, the Academy developed a global research agenda that identifies the most pressing gaps in nutrition -- and delineates how to close those gaps. Now the Sackler Institute through unprecedented public-private partnerships is creating the next step: Catalyzing scientific research to affect real change.

Accelerating Research to Fight Alzheimer’s Disease: The Academy is helping accelerate new treatment and prevention methods to fight the growing scourge of Alzheimer’s disease and dementia, a growing global health concern that will devastate families and cause economic devastation to countries as their populations age. The Academy pioneered the Alzheimer’s Summit 2013 with CEOi and the National Institutes on Aging as a ramp up to the G-8 commitment to create new research models and funding methods. Its goal: Breakdown research barriers and competing agendas to bring new treatment methods to market sooner.

BUILDING A KNOWLEDGE ECONOMY THROUGH CAPACITY DEVELOPMENT

The Academy supports the next generation of scientific innovation by educating and supporting scientists at every stage of their careers. Among its seminal programming:

Solving the Global STEM Education Crisis: The Academy launched the first Global STEM Alliance in 2013 to solve the growing gap between the number of students adequately trained for future jobs in science, technology, education and math (STEM). Governments throughout the world are joining the alliance. And with its partner CISCO, the Academy is developing the world’s first digital network for STEM education, further enhancing the Academy’s in-country programs.

Speeding Scientific Innovation: The Academy is ensuring the next generation of scientific brilliance. It has created and now administers the Blatvatnik Awards for Young Scientists, which recognizes and rewards the most enterprising scientific minds in the United States. Next up: Creating new partnerships to take this gifted network global.

ADVISING THE WORLD’S VISIONARY GOVERNMENTS ON SCIENTIFIC ENTERPRISE

The Academy leverages its knowledge, expert network, and neutrality to counsel governments on increasing their global competitiveness and creating public policy that will support and advance scientific knowledge and economic viability. Among its work, advising: the Federation of Russian on innovation, Qatar on the nation’s research priorities, Malaysia on science and technology assets, and Mexico City on creating an urban knowledge ecology.
The Global Health Impact Forum: A unique platform for pro-social family offices and foundations in support of the goals and objectives of the United Nations System:

His Excellency Dr. Hamadoun Touré  
Secretary-General of the International Telecommunication Union (ITU)

Dr. Hamadoun I. Touré, Secretary-General of the International Telecommunication Union (ITU) since January 2007, was re-elected for a second four-year term in October 2010. As Secretary-General, Dr Touré is committed to ITU’s mission of connecting the world, and to helping achieve the Millennium Development Goals through harnessing the unique potential of Information and Communication Technologies (ICTs). A long-standing champion of ICTs as a driver of social and economic development, Dr Touré previously served as Director of ITU’s Telecommunication Development Bureau (BDT) from 1998-2006. In this role he placed considerable emphasis on implementing the outcomes of the World Summit on the Information Society (WSIS), launching projects based on partnerships with international organizations, governments, the private sector and civil society.

Ambassador Gyan Chandra Acharya  
High Representative for the Least Developed Countries, Landlocked Developing Countries and Small Island Developing States

Ambassador Gyan Chandra Acharya, is the United Nations Under Secretary-General and High Representative for the Least Developed Countries, Landlocked Developing Countries and Small Island Developing States (UN-OHRLLS). Prior to his appointment, he served as the Permanent Representative of Nepal to the United Nations, in which capacity he contributed since 2009 as Chair of the Global Coordination Bureau of the Group of Least Developed Countries, to the successful conclusion of the Fourth United Nations Conference on the Least Developed Countries and the follow-up process. He was also closely involved in the 2010 Millennium Development Goals mid-term review process and the United Nations Conference on Sustainable Development (Rio+20), held recently in Rio de Janeiro, Brazil. He was also a member of the Bureau of Landlocked Developing Countries and was elected Chair of the Commission on Social Development. From 2010 to 2011 he served as Chair of the Peace building Commission’s Working Group on Lessons Learned.

His Excellency Dr. Thomas Gass  
Assistant Secretary-General, Department of Economic and Social Affairs

Dr. Thomas Gass was appointed by the Secretary-General as Assistant Secretary-General for Policy Coordination and Inter-Agency Affairs in UN DESA and he took office on 3 September 2013. He brings with him wide-ranging experience in bilateral and multilateral development cooperation. From 2009 to 2013, he served as Head of the Mission of Switzerland to Nepal (Ambassador and Country Director of the Swiss Agency for Development and Cooperation), where he established the Embassy of Switzerland in Nepal, and ensured the delivery of a development cooperation programs of up to 33 million dollars a year. He also chaired the Donors of the Nepal Peace Trust Fund, the main instrument for international support to Nepal’s peace process. Before his posting to Nepal from 2004 to 2009, Mr. Gass was Head of the Economic and Development Section at the Permanent Mission of Switzerland to the UN in New York, where he represented Switzerland’s interests, in particular the Economic and Social Council (ECOSOC), its subsidiary Commissions, the General Assembly and the Executive Boards of the major UN Funds and Programs. During this time, Mr Gass was the Chair of the Donor Group of the UN Global Compact.

Dr. Roland Rich  
Executive Director, United Nations Office for Partnerships

Dr. Roland Rich, an Australian national, assumed his position as Executive Head of the United Nations Democracy Fund (UNDEF) in 2007. UNDEF’s primary purpose is supporting democratization around the world by funding projects that strengthen the voice of civil society, promote human rights, and encourage the participation of all groups in democratic processes. Dr. Rich is concurrently Officer-in-Charge of the United Nations Office for Partnerships (UNOP) which serves as a gateway for corporate and philanthropic partnership opportunities with the UN family. Dr. Rich brings over 30 years of experience as a diplomat, a scholar and a democracy promotion practitioner. Prior to his appointment to UNDEF, Dr. Rich was at the Australian Defense College, teaching and mentoring colonel-level officers. In 2005, Mr. Rich was a research Fellow at the National Endowment for Democracy in Washington DC. Between 1998 and 2005, he was the Director of the Centre for Democratic Institutions at the Australian National University which is Australia’s democracy promotion institute for the Asia-Pacific region.

* Invited
The Global Health Impact Forum:

Professor the Lord Darzi of Denham
Chairman of Departments of Surgery at
Imperial College London

Professor Darzi holds the Paul Hamlyn Chair of Surgery at Imperial College London, the Royal Marsden Hospital and the Institute of Cancer Research. He is Director of the Institute of Global Health Innovation at Imperial College London and an Honorary Consultant Surgeon at Imperial College Hospital NHS Trust. He was knighted for his services in medicine and surgery in 2002. In 2007, he was introduced to the United Kingdom's House of Lords as Professor the Lord Darzi of Denham and appointed Parliamentary Under-Secretary of State at the Department of Health. Professor Darzi serves as the United Kingdom's Global Ambassador for Health and Life Sciences. In 2013 he hosted the World Innovation Summit for Health in Doha, Qatar, under the Patronage of Her Highness Sheikha Moza bint Nasser al Missned and Qatar Foundation.

Mr. Ellis Rubinstein
President and CEO
The New York Academy of Sciences

Mr. Ellis Rubinstein is an innovator and change agent. As a science journalist, his work merited 3 National Magazine Awards, the Pulitzer Prizes of the American periodicals industry. As a leading editor at IEEE Spectrum, Science 86, and Newsweek — and as Editor of the renowned journal Science for a decade — Rubinstein increased impact and circulation through landmark articles and special issues, redesigns and re-conceptualizations, internationalization in coverage and circulation, and innovation in Web publishing. Now, as leader of a unique global academy of sciences, he has created a series of unprecedented initiatives that are powered by an extraordinary network of the world’s leading experts and academic and industry institutions.

Since joining the 196-year-old New York Academy of Sciences in November 2002, Mr. Rubinstein has increased membership to 22,000 scientists in 140 countries. The President’s Council that he created has 27 Nobel Laureates and a score of CEOs and government leaders from across the globe. The Academy’s Board includes 3 Nobel Laureates, several philanthropists, the Presidents of 6 universities and academic medical centers, and the heads of research of IBM, Pfizer, Johnson & Johnson, and PepsiCo.

Mr. Aly Sheezar Jeddy
Partner, HealthCare & Institutional Coverage, The Abraaj Group

Mr. Aly Sheezar Jeddy joined The Abraaj Group as a Partner in 2014. Mr. Jeddy plays Group-wide investment and firm management roles as well as supporting the firm’s investor relations activities in the United States. Since 2005, he has worked closely with Abraaj on firm strategy, organizational design, change management, skill-building, growth and innovation. Mr Jeddy joined Abraaj after twenty years at McKinsey & Company where he was a Senior Partner based in New York and Head of the Private Equity and Principal Investing Practice in the Americas. Mr Jeddy graduated in Economics and Engineering Science from Dartmouth College as Valedictorian. He earned his J.D. from the Yale Law School with Honors. He serves on the Board of Overseers of the International Rescue Committee, the Board of Trustees of The Dalton School and the Board of Trustees of the Aziz Jehan Begum Trust for the Blind. He is a Senior Advisor to Endeavor. He is also a member of the Dartmouth College Alumni Council.

Professor Freddie Hamdy
Nuffield Professor of Surgery, Head of Department and Professor of Urology

Professor Freddie Hamdy is Head of the Nuffield Department of Surgery, Nuffield Professor of Surgery, Professor of Urology and Honorary Consultant Urological Surgeon at the Oxford Radcliffe Hospitals and Fellow of Balliol College. He has spent the past 10 years as founding Chair of Urology and was Director of the Division of Clinical Sciences, Head of Oncology at the University of Sheffield. He trained in Surgery and Urology at Liverpool, Sheffield and Newcastle. He was the first recipient of the Crystal Matula award from the European Association of Urology in 1996, and the Golden Telescope award from the British Association of Urological Surgeons in 2002. He has been Chairman of the Scientific Committee at the European Association of Urology since 2004, is a Board member of the French National Cancer Institute (INCa), and was elected Fellow of the Academy of Medical Sciences in 2007.
The Global Health Impact Forum:

Mr. Miles Ayling
Director of Innovation, NHS England

Mr. Miles Ayling, Director of Innovation, NHS England & Chair of the NHS Innovation Challenge Prizes Expert Panel. Whilst working for the Department of Health and NHS England, Director of Innovation, Mr. Ayling has been responsible for a number of significant healthcare reform programs including the introduction of legislation on care trusts, delivery of commissioning a patient led NHS and the reconfiguration of services in Primary Care Trusts. He also led the establishment of NHS Global and co-authored 'Innovation Health and Wealth' (IHW) which aims to transform the NHS' approach to innovation. Mr. Ayling created, designed and introduced the NHS Regional Innovation Awards and is the Interim Chair of the NHS Challenge prize program.

Ms. Kate Bingham
Managing Partner, SV Life Sciences, London

Ms. Kate Bingham, Managing Partner, SV Life Sciences, London. The SVLS team manages five private venture capital funds with approximately $1.9 billion of capital under management. The firm employs a diversified strategy within life sciences in order to selectively capitalize on an expanding opportunity in biotech, medical devices and health-care services. Ms. Bingham is one of the pre-eminent life sciences private equity specialists in the UK. In addition to her role as a Managing Partner at SV Life Sciences, she sits on numerous advisory boards such as the BVCA and past board member of the UK’s Bio Industry Association. Ms. Bingham read for a Biochemistry degree at Oxford University before undertaking an MBA at Harvard as a Kennedy scholar. Prior to joining SV Life Sciences, she spent time as a Strategy Consultant for Monitor and has worked in business development at Vertex Pharmaceuticals.

Sir Andrew Cash
Chief Executive, Sheffield Trust

Sir Andrew Cash, Chief Executive, Sheffield Trust, founding Chair of the Foundation Trust Network (FTN) and previously served as Director General, Department of Health, England and co-chair of the Department of Health/Ministry of Defense Partnership Board. He is a visiting Professor in Leadership and Development at the Universities of Sheffield and York. He chairs the NHS Employers Policy Board, is Vice Chair of the NHS Confederation, is a member of the Innovation, Health and Wealth Implementation Board.

Sir Jonathan Michael
Chief Executive Oxford University Hospitals NHS Trust

Sir Jonathan Michael, Chief Executive Oxford University Hospitals NHS Trust and Trustee of the King's Fund. His previous roles include Managing Director of BT Health, Chief Executive of Guys and St Thomas's Hospitals NHS Foundation Trust and Chief Executive of University Hospitals Birmingham NHS Trust. Sir Jonathan, who began his career as a consultant physician, has also acted as Chairman of the Board for NHS Innovations London and the NHS Foundation Trust Network, and was knighted for services to the NHS in 2005.
The Jones family is perhaps best known as co-founders of the Humana hospitals and insurance groups. David is a well-respected voice in healthcare business, innovation and education. David brings a strong and well-rounded background in business, law and banking to his work at Chrysalis Ventures, which he founded in 1993. David is active in civic and charitable affairs on both national and local levels. He is a member of the invitation-only Healthcare Executive Network, which collectively examines the strategies necessary to create and sustain a world-class healthcare delivery system. In addition, David is a director of the Humana Foundation, Inc. and is active on the grants committee of a private foundation. He is also a Board member of the National Committee on U.S.-China Relations.

Scott Parazynski, M.D.
Astronaut – Everest Climber – Physician – Innovator

Scott is a respected and well-known physician, 5 time NASA space shuttle astronaut, pilot and 'in his spare time' summited Mt. Everest. He currently serves as Chief Medical Officer and Director, UTMB Center for Polar Medical Operations. Scott is also Chairman of the Board, Challenger Center for Space Science Education, one of the largest and most influential STEM education organizations in the world, engaging over 400,000 school kids each year through hands-on space simulations. Scott is the recipient of a number of prestigious awards, including: five NASA Spaceflight Medals, two NASA Distinguished Service Medals, two NASA Exceptional Service Medals, and two Vladimir Komarov Diplomas from the Fédération Aéronautique Internationale.

Mehmood Khan, M.D.
Executive Vice President, PepsiCo
Chief Scientific Officer, Global Research and Development

Mehmood Khan, M.D., is executive vice president and chief scientific officer, global research and development, PepsiCo. As chief scientific officer, Mehmood leads company-wide research and development (R&D); recruits highly regarded clinical scientists, global health leaders and medical experts; launches research projects with leading universities; and opens advanced R&D facilities. Prior to joining PepsiCo, Mehmood was president, Takeda Global Research & Development Center, overseeing Takeda Pharmaceuticals Company's worldwide R&D efforts. Previously, Mehmood was as a faculty member at the Mayo Clinic and Mayo Medical School in Rochester, Minn., serving as director of the Diabetes, Endocrine and Nutritional Trials Unit in the endocrinology division. He also spent nine years leading programs in diabetes, endocrinology, metabolism and nutrition for the Hennepin County Medical Center in Minneapolis.
The Global Health Impact Forum:

Maj. Gen. Gale Pollock
Former Deputy Surgeon General of the United States Army

MG Gale S. Pollock (Ret) served as Commander, US Army Medical Command and Acting Surgeon General of the Army in 2007 (the first woman, non-physician to have this role in any of the military services with a $9.7B annual budget). Simultaneously, she served as the 22nd Chief of the Army Nurse Corps. Following her retirement from the Army, she was the founding Executive Director of the Louis J. Fox Center for Vision Restoration at the University of Pittsburgh and associate professor at the University of Pittsburgh School of Medicine and School of Nursing. In 2011, MG Pollock was a Fellow in Harvard University’s Advanced Leadership Initiative. She currently focuses her time on the vision impairment (one of the top ten disabilities in America) and veteran health issues. She remains an adjunct clinical professor of Yonsei University Graduate School of Nursing in Seoul, Korea and serves as an Advisory Board Member for both profit and not for profit organizations. MG Pollock is a Fellow in The American College of Healthcare Executives (FACHE) and the American Academy of Nursing (FAAN).

Ms. Liesel Pritzker Simmons
Co-Founder and Principal, Blue Haven Initiative

Liesel Pritzker Simmons is the Co-Founder and Principal of the Blue Haven Initiative, a family office dedicated to deploying different kinds of capital (for- and nonprofit) to solve social problems. Liesel is the Co-Founder of the IDP Foundation, Inc. (www.idpfoundation.org) a private foundation with a mission to mobilize resources and strategic support to increase educational opportunities. Established in 2008, the IDP Foundation has supported and developed a wide range of programs in the education sectors most notably the innovative IDP Rising Schools Program in Ghana, which leverages microfinance networks to empower low cost private schools with trainings and financial services. Liesel is a Co-Founder of Opportunity International’s Young Ambassadors for Opportunity (YAO), a global network of young professionals who are passionate about microfinance. She is currently the Chairman of the Board of YAO and Director on the Board of The Synergos Institute. Liesel attended Columbia University, where she studied African History. She has volunteered at schools and microfinance institutions in India and Tanzania, but unfortunately has forgotten most of her Swahili.

Michael Lenardo M.D.
Section Chief at Laboratory of Immunology, NIAID, NIH

Dr. Lenardo graduated with a B.A. from the Johns Hopkins University and an M.D. from Washington University, St. Louis. He performed clinical work in internal medicine and research at the University of Iowa and received postdoctoral training at the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology. He established an independent research unit in the Laboratory of Immunology in 1989 and became a senior investigator and section chief in 1994. Dr. Lenardo serves on several editorial boards and has given numerous lectures around the world on his work on the molecular regulation of immune homeostasis. His work focuses on lymphocyte apoptosis, autoimmunity, and genomics of the immune system. He was one of the founders of the NIH-Oxford-Cambridge Scholars program for doctoral training and the NIH M.D./Ph.D. partnership program.

Steve Shaya, M.D.
Chief Medical Officer, J&B Medical

Steve is Chief Medical Officer of Shaya family office owned J&B Medical, one of the nation’s leading specialty medical product supply and distribution companies. J&B Medical serve over 100,000 healthcare professionals and hospitals across the country and have operations in 24 countries around the world.

Steve is also a member of ’Pietas’, a global nonprofit dedicated to providing medical solutions for rural and indigenous communities. The Pietas project in Latin America is improving access to high-quality medical treatment via the latest Telemedicine technology and bridging the urban Vs. rural medical treatment gap in Latin America. Pietas Telemedicine solutions will also allow International Organizations (such as WHO) rapidly and cost effectively gather accurate information on the containment and treatment of contagious and pandemic diseases.
The Global Health Impact Forum:

**Richard Siegel MD PhD**  
Clinical Director of the National Institutes of Arthritis And Musculoskeletal Diseases

Richard Siegel trained at the University of Pennsylvania, initially as an M.D./Ph.D. student in immunology and then as a resident in internal medicine and rheumatology fellow. He moved to the NIH in 1996 to do postdoctoral training with Michael Lenardo in the Laboratory of Immunology in the National Institute of Allergy and Infectious Disease. There he studied apoptosis signaling and the molecular basis of its impairment in patients with inherited mutations in Fas/CD95 and the Autoimmune Lymphoproliferative Syndrome (ALPS). In 2001, Dr. Siegel moved to NIAMS as a tenure-track investigator. His current research interests include regulation of cellular survival and death in immune system by TNF receptor and other signaling pathways, and the relevance of these pathways to autoimmune diseases and immune tolerance. He is a member of the American Society of Clinical Investigation and has served on the editorial board of the Journal of Biological Chemistry. In 2006, with Michael Lenardo, Dr. Siegel founded the MD/PhD partnership training program.

**Mr. Ian Simmons**  
Co-Founder and Principal, Blue Haven Initiative

Mr. Ian Simmons is Co-Founder and Principal of Blue Haven Initiative, a family office dedicated to deploying for-profit and non-profit capital to solve social problems.

For over a decade, Mr. Simmons has conceived and catalyzed projects to improve democracy. Results of various projects featured in The New York Times, The Wall Street Journal, The Los Angeles Times, and The Washington Post, as well as on CBS, NBC, ABC, and CNN. For example, Mr. Simmons was the silent partner in co-founding and seed-funding ActBlue, which makes it easier for citizens to create change. ActBlue has channeled over three million individual donations totaling more than $373 million to candidates across the United States. Mr. Simmons graduated with honors from Harvard College in 2000.

**Mr. Yasuhiro Oishi**  
President Kyocera Communications Inc.

Kyocera Communications Inc. (KCI). KCI is a wholly owned subsidiary of Kyocera International Inc. that provides the customer engineering and service functions for Kyocera- and Sanyo-branded wireless devices in the Americas. Mr. Oishi joined Kyocera Corp. in 1985 with a degree in commercial science from Doshisha University in Japan. Upon Kyocera’s acquisition of the mobile phone division of Qualcomm Inc. in 2000, he moved to San Diego to become part of Kyocera’s U.S. wireless equipment business. Through 2008 he served as vice president of procurement, after which he spent two years as vice president of supply chain and production. Kyocera acquired the global mobile phone division of Sanyo Electric Co., Ltd. in 2008, and consolidated its U.S. wireless operations to create KCI the following year. Oishi became KCI’s vice president and general manager of global sales and marketing in 2010.

**Mr. Gregory C. Simon**  
Chief Executive Officer, Poliwogg

Mr. Simon has held senior positions in both houses of Congress and the White House, been a senior executive at Pfizer, led FasterCures/The Center for Accelerating Medical Solutions - the national patient advocacy nonprofit he co-founded with Mike Milken and served as a strategy consultant to a number of international technology CEOs. At the Milken Institute he led efforts to reform policies governing biopharmaceutical discovery and development, with the goal of bringing a greater number of lifesaving medicines more quickly to doctors and patients. Most recently Mr. Simon was Senior Vice President for Patient Engagement at Pfizer, Inc. where he focused on engaging patients more productively in research and clinical trials and on helping Pfizer develop policies, practices, and medical solutions to improve health, happiness and productivity. He was head of Pfizer’s Worldwide Policy group where he led a global team of professionals in: 1) worldwide government policy, 2) science policy, 3) economic policy and research, and 4) international policy. He advised the CEO on the company’s efforts in Healthcare Reform. Mr. Simon has developed a reputation as a visionary strategist, dynamic public speaker and writer, and as a knowledgeable analyst of emerging trends in healthcare, information technology, drug research and development, and patient advocacy.
Irene Pritzker became a founding member and President of the IDP Foundation, Inc. in 2008. It is her belief that education is the way to conquer the world’s greatest challenges, and that everyone should have equal access to education to provide hope, opportunity and economic impact on their homeland. The IDP Foundation is dedicated to developing programs in education that are sustainable and move away from aid dependent models. She believes a combination of smart philanthropy and investment solutions can be galvanized to make that future a reality.

Exemplifying this goal is the IDP Rising Schools Program, a microfinance venture targeting existing but very poor private schools in Ghana. After a successful pilot with 105 schools, the program is scaling up by adding 1200 schools over the next four years.

As a great advocate of sustainable and market-driven solutions, Irene Pritzker is frequently invited to share the work of the IDP Rising Schools Program at the United Nations and other international fora focused on education. In 2010, the Foreign Policy Association awarded Mrs. Pritzker the Global Philanthropy Award during the World Democracy Forum in New York.

Ms. Kay Koplovitz
Co-founder Springboard Enterprises and Founder USA Network

Ms. Koplovitz co-created Springboard Enterprises, a national organization that fosters venture capital investments in women-led high growth companies. She also co-founded Boldcap Ventures, a venture capital fund backed exclusively by leading women executives. Boldcap invests principally in early to mid-stage companies in the media, technology, and healthcare sectors. Ms. Koplovitz is the founder of USA Networks and the first woman network president in television history. A pioneer in cable television networks and new media ventures, she led the emergence of cable television from the backcountry of America to challenge the broadcast networks for coveted audiences. She continues to be a leader in raising venture capital for women entrepreneurs and in launching new programming companies that challenge the frontiers of the digital age. Ms. Koplovitz is also Chairman and CEO of Koplovitz & Company, LLC, which provides advisory services to entertainment companies, sports organizations, advertisers and distributors and advises companies on growth strategies.

Mr. Amir Dossal
Chairman Global Partnerships Forum

Mr. Dossal is perhaps best known for his appointment by the media mogul Ted Turner to manage his $1 billion gift to the United Nations and as Executive Director of the UN Office for Partnerships. Under Dossal's leadership the UN Foundation attracted additional investments in excess of $560 million (supporting 450 international projects for women and children’s health, climate change and bio-diversity) from leading family offices, foundations and corporations including the Bill and Melinda Gates Foundation, the Rockefeller Foundation, Coca-Cola and the American Red Cross. Mr. Dossal is Founder and Chairman of the Global Partnerships Forum, an international platform working to address economic and social challenges, through the creation of innovative partnerships. He is also the Co-Initiator of the Pearl Initiative, a CEO-led program, promoting transparency and accountability in the Gulf Region.

Dr. Robert E. Ratner is Chief Scientific & Medical Officer for the American Diabetes Association, the nation’s largest voluntary health organization leading the fight to Stop Diabetess®. Dr. Ratner provides leadership and oversight of scientific and medical activities including research, clinical affairs, program recognition and certification, medical information and professional education. In this capacity, he will oversee the Association’s support of a broad range of professional education activities and the development of the American Diabetes Association Clinical Practice Recommendations, clinical consensus reports and expert opinions. In 2013, the Association provided $36 million in research funds, funding more than 450 grants at 130 leading U.S. research institutions. Prior to joining the American Diabetes Association, Dr. Ratner was a Professor of Medicine at Georgetown University Medical School and Senior Research Scientist at the MedStar Health Research Institute in metropolitan Washington, DC.

Robert E. Ratner, MD
Chief Scientific and Medical Officer, American Diabetes Association

Ms. Irene D. Pritzker
President, IDP Foundation
The Global Health Impact Forum:

Mr. John H. Friedman
Founding and Managing Partner,
Easton Capital

Mr. John H. Friedman, Founding and Managing Partner, Easton Capital, a leading private equity firm focused only on those opportunities that offer services or products that can materially improve the healthcare people receive or reduce its cost. Prior to founding Easton Capital, Mr. Friedman was the founder and Managing General Partner of Security Pacific Capital Investors. Security Pacific Capital Investors was a $200-million private equity fund geared towards expansion financings and recapitalizations and Managing Director and Partner at E.M. Warburg, Pincus & Co. Inc. where he spent eight and a half years. Previously, John was an attorney with Sullivan and Cromwell. Mr. Friedman currently serves on the Boards of Promedior, Trellis Bioscience, Cardiovascular Systems, PreceptiMed, TigerText, Within3, and Precise Light. He was also co-chairman of the President’s Council at the Cold Spring Harbor Laboratory and serves as a Trustee of The New Museum of Contemporary Art and The Sculpture Center.

Saralyn Mark, M.D.
Senior Medical Advisor to the Office on Women's Health and President,
SolaMed Solutions

Saralyn Mark, MD, a world renowned leader in women's health, is an endocrinologist, geriatrician and women's health specialist. She was the first Senior Medical Advisor to the Office on Women's Health within the Department of Health and Human Services. She designed the first women's health fellowship in the US, helped create the National Centers of Leadership in Academic Medicine, the National Centers of Excellence in Women's Health, and landmark educational campaigns on critical health issues. She has published and delivered over 600 lectures and is a frequent health media expert. Dr. Mark works with agencies, academia, industry and NGOs around the globe. As President of SolaMed Solutions, LLC, Dr. Mark serves as a medical and scientific policy advisor to the White House, NASA and other organizations dedicated to improving health on Earth and in space. She holds 4 academic appointments including at Yale and Kings College-London. She is author of Stellar Medicine: A Journey Through the Universe of Women’s Health.

Ms. Kedge Martin
Co-founder of Longbow

Ms. Kedge Martin, Co-founder and CEO of Longbow NXG, the leading academy for the development of potential and purpose in those inheriting great wealth, has more than twenty five years’ experience of strategy and operational leadership in the not-for-profit and business sectors in the UK, Europe and Africa. She is a founder member of TRH Duke and Duchess of Cambridge and HRH Prince Harry’s Charities Forum. Her particular expertise is in organizational turn-around and growth. Ms. Martin was CEO of Sentebale, Prince Harry’s charity for African Orphans and vulnerable children in Lesotho working with HRH in the UK and internationally in the US, South America, Africa, Middle East and Europe. Previously Ms. Martin was CEO of WellChild, the UK's first paediatric research charity founded in 1977. While managing a significant medical research portfolio, she expanded the organisation's reach into care, support and education programmes for chronically sick children and their families. WellChild set up the first paediatric Pain Research Centre at London's Great Ormond Street Hospital and Europe’s first genetic epidemiology centre. She was a Board Member of the UK's Association of Medical Research Charities.

Mr. Jesse H. Ausubel
Director of the Program for the Human Environment of The Rockefeller University

Mr. Ausubel studies environmental science and related industrial evolution. His research focuses on long-term technical change; its relationship with the evolving productivity of energy, materials, land and other resources; and consequences for human populations. Under auspices of the Alfred P. Sloan Foundation, Mr. Ausubel helped carry out the Census of Marine Life, an international observational program to assess and explain the diversity, distribution and abundance of life in the oceans. Involvement in the marine census led to an interest in environmental genomics, and researchers in the program now advance the use of short DNA sequences for species identification, the so-called “Barcode of Life.” In addition, Mr. Ausubel and his collaborators participate in the growing Encyclopedia of Life, a Web portal that aims to include pages for all of Earth’s 1.9 million named species. Under Sloan auspices, the program also helps plan and operate the cooperative international Deep Carbon Observatory, which is searching for the origin and limits of life and for the roots of petroleum and natural gas.
Mr. Pablo Legorreta, Founder and Chief Executive Officer, Royalty Pharma. Mr. Legorreta founded Royalty Pharma in 1996, after creating and managing two “proof of principle” investment vehicles in 1993 and 1994 that invested in royalty interests in two leading biotechnology products. Prior to founding these investment vehicles, Mr. Legorreta spent ten years at Lazard Frères where he provided cross-border merger and acquisition and corporate finance advisory services to US and European corporations.

Dr. Sam Hall, PhD, Associate, Apple Tree Partners. Dr. Hall has over a decade of experience in the life sciences across roles as a private equity investor, investment banker and basic scientist. Prior to joining Apple Tree in 2013, he was a researcher at the University of Cambridge in the UK, where his work focused on novel therapeutic strategies for autoimmune diseases. Previously Dr. Hall was a member of the investment team at Symphony Capital, a private equity firm dedicated to investments in biopharmaceutical development.

Ms. Melissa Stevens, Deputy Executive Director, FasterCures. Ms. Stevens manages planning and implementation of FasterCures programs and directs the organization's medical philanthropy efforts including the Philanthropy Advisory Service.

Mr. Zac Russell, Board of Directors, Russell Family Foundation. Mr. Russell has always been passionate about how to tell a story better. He founded Russallo in 2013, a narrative consulting firm focused on listening, designing and implementing holistic communication and marketing plans for a wide variety of organizations. He is a long time advocate for next generation philanthropy, impact investing, and global social entrepreneurship for non-profits and foundations. Mr. Russell has worked as a Hawaiian cattle hand, Marketing for FOURPOINTS a French international equities fund manager, and with One Nation, an Initiative working with American Muslim communities to end discrimination. He is a graduate of Sarah Lawrence College with a concentration in Nonfiction Writing and global economics. Mr. Russell serves on the board of directors of the Russell Family Foundation as a part of their investment committee.
The Global Health Impact Forum:

Mr. Josh Cohen, Co-Founder, Managing Director, City Light Capital

Mr. Josh Cohen, Co-Founder, Managing Director, City Light Capital, Co-Founder, Managing Director, City Light Capital, investing in companies tackling society’s toughest challenges; a firm that he co-founded in 2004. He is currently on the Boards of LicenseStream and City Light Carbon and is an Observer to the Boards of 2Tor and ShotSpotter. He was formerly an Observer to the Board of Arxceo. Mr. Cohen had previous venture capital experience working with a family office in St. Louis and the SV Group.

Mr. Brian Trelstad, Managing Director, Bridges Ventures

Mr. Brian Trelstad, Managing Director, Bridges Ventures; a specialist fund manager, dedicated to using an impact-driven investment approach to create superior returns for both investors and society at-large. Brian has over 10 years of impact investing experience, having served until 2012 as the Chief Investment Officer of Acumen Fund, where he oversaw investments into companies that were delivering health, water, energy, and agriculture services to economic base of the pyramid in South Asia and Sub-Saharan Africa.

Mr. Alexander Saint-Amand, President and CEO of GLG

Mr. Alexander Saint-Amand, President and CEO of GLG, the world’s largest membership for professional learning and expertise. He is a founding member of the company and previously served as its Chief Operating Officer. During his tenure and under his leadership, GLG has grown from a small start-up to one of New York City’s most successful venture-backed companies, having facilitated over 1.5 million teaching and learning projects, and now with over 20 offices in 12 countries.

Mr. Steve McLean, Partner, Arsenal Capital Partners

Mr. Steve McLean, Partner, Arsenal Capital Partners; a progressive private equity firm with $1.65 billion under management that facilitates transformational growth and change through a collaborative approach. Prior to joining Arsenal in 2010, Mr. McLean was a Managing Director at Courtagen Capital Group and its predecessor companies where he invested in healthcare companies. Mr. McLean was a Founding Partner of Merrill Lynch Capital Partners, Inc. (and its successors, Stonington Partners and Arena Capital Partners) and has helped to raise and manage aggregate private equity funds of $2.8 billion. Mr. McLean received a BS. in Economics from University of Pennsylvania and a MBA from the Wharton School. Mr. McLean currently serves on the Board of Directors of CentriHealth, Inc., Courtagen Bioscience, RS Medical Corporation, and The WIRB-Copernicus Group, Inc., and is also the Chairman of the International Biomedical Research Alliance.
Mr. Adair Newhall, Principal, Domain Associates; Domain was one of the first venture capital firms to exclusively invest in the life sciences sector. Domain has been involved in the formation of more than 250 companies, with more than $2.7 billion in capital raised to-date. Mr. Newhall joined Domain in August 2009 and became a Principal in 2014. At Domain, Mr. Newhall assists with the review of new investment opportunities and helps current portfolio companies with financing strategies and business development processes. While at Domain, Adair worked on business development activities for Calixa Therapeutics, a Domain portfolio company, which was acquired by Cubist Pharmaceuticals. Prior to Domain, Mr. Newhall also worked for two other Domain portfolio companies: Esprit Pharma and ESP Pharma. Mr. Newhall is a founding member of the life science non-profit SparkBio, and was a founding member of the Young Leaders Cancer Council of the Lance Armstrong Foundation and co-founder of the UVa Venture Summit.

Mr. Stanton (Stan) J. Rowe, Chief Scientific Officer & Corporate Vice President, Edwards Lifesciences and also serves as Corporate Vice President, Advanced Technology. He joined the company in 2004 when Edwards acquired Percutaneous Valve Technology, of which he was president and CEO and helped to found in 1999. Previously, Rowe was Corporate Vice President of Business Development and Strategic Planning for Datascope and was Vice President of Business Development for Johnson & Johnson's Interventional Systems Division (JJIS), responsible for the company’s coronary stent development efforts.

Andrew Schiff, M.D., Managing Director, Aisling Capital a leading investment firm focused on novel approaches toward the diagnosis, prevention, and treatment of life-threatening illnesses. Dr. Schiff joined Fund I in September of 1999 and has served as a Managing Partner since 2002. Prior to joining Fund I, Dr. Schiff practiced internal medicine at The New York Presbyterian Hospital where he maintains his position as a Clinical Assistant Professor of Medicine. Dr. Schiff currently serves as a director of ARMGO Pharma, Inc., Miramar Labs, Inc., TransEnterix, Inc. and Zeltiq Aesthetics, Inc. Previously he served as a director of Adams Respiratory Therapeutics, Inc., ArgiNOx Pharmaceuticals, Inc., Barrier Therapeutics, Inc., Bioenvision, Inc., Cempra Pharmaceuticals, Inc., CardioKin, Inc., Dynova Laboratories, Inc., Myogen, Inc., Planet Technologies, Inc., Sirion Therapeutics, Inc. and SkinMedica, Inc. Dr. Schiff received his M.D. from Cornell University Medical College, his M.B.A. from Columbia University, and his Sc.B. with honors in Neuroscience from Brown University.

William W. Li, M.D.; President, Medical Director, and Co-founder of the Angiogenesis Foundation. Dr. W. Li trained in the lab of Dr. Judah Folkman, pioneer of the angiogenesis field, and has been actively engaged in angiogenesis research and clinical development for 22 years. Under Dr. Li’s leadership, the Foundation has developed a unique social enterprise model based on international collaborations with leading medical academic centers, biopharmaceutical companies, and government agencies, including the National Institutes of Health, National Cancer Institute, and the Food and Drug Administration. As President, Dr. Li has testified and presented before congressional and other government panels on the impact of angiogenesis in healthcare, and lectures widely on angiogenesis-related topics in front of clinical, government, and industry audiences. He is involved in national and international efforts to advance the applications of angiogenesis-based therapeutics across diverse medical fields, including oncology/hematology, cardiology, ophthalmology, vascular surgery, dermatology, and wound care.
The Global Health Impact Forum:

Mr. Paul LaViolette, Managing Partner SV Life Sciences. The SVLS team manages five private venture capital funds with approximately $1.9 billion of capital under management. The firm employs a diversified strategy within life sciences in order to selectively capitalize on an expanding opportunity in biotech, medical devices and health-care services. Previously Mr. LaViolette was Chief Operating Officer at Boston Scientific Corporation (BSC), also served at BSC as COO, Group President, President-Cardiology and President-International. During his 15 years at BSC, he served as COO, Group President, President-Cardiology and President-International. During his tenure, the Company grew revenues over 20 times. He also spearheaded over 20 acquisitions and led extensive product development, operations and worldwide commercial organizations. Mr. LaViolette previously held marketing and general management positions at CR Bard, and various marketing roles at Kendall (Covidien).

Mr. Paul LaViolette
Managing Partner SV Life Sciences

Dr. Nandan Padukone, Ph.D., MBA, Vice President Office of Commercialization & Ventures, (OCV) Joslin Diabetes Institute of Harvard Medical School. Dr. Padukone helped launch the OCV as a business center of Joslin Diabetes Center to create strategic relationships with industry and leverage Joslin’s world-leading expertise in diabetes-directed research and clinical care. Dr. Padukone has 17 years in biotechnology management and entrepreneurial ventures involving diagnostics (Nuvera), therapeutics (Altus Pharma), bioinformatics (Silico Insights), and renewable energy (NREL). He helped launch Nuvera Biosciences as founding CEO in 2005, a venture focused on cancer therapy and pharmacogenomics, in collaboration with MD Anderson Cancer Center.

Dr. Nandan Padukone Ph.D., MBA
Vice President, Joslin Diabetes Institute of Harvard Medical School

Mr. Labeeb Abboud, Senior Vice President Business Development and Strategy & General Counsel, International AIDS Vaccine Initiative (IAVI), a non-profit organization focused on accelerating the development of safe, effective, accessible, prophylactic AIDS vaccines. At IAVI, a product-development-partnership, he has helped establish vaccine research and development partnerships with biotech and pharmaceutical companies, academic institutes and governments, as well as clinical research programs in India and several African countries. In addition, Mr. Abboud helped launch, and has served since December 2011 as a Fund Manager of, the Global Health Investment Fund, a social impact fund designed to accelerate late stage global health product development, including drugs, vaccines, diagnostics, devices and maternal and child health interventions. He is also a member of the Expert Advisory Group for the Medicines Patent Pool, which seeks to increase access to affordable and appropriate HIV medicines in developing countries, has served as a director of several non-profit organizations in the fields of global health and education, and is a member of the Council on Foreign Relations.

Mr. Labeeb Abboud
Senior Vice President, International AIDS Vaccine Initiative and Fund Manager, Global Health Investment Fund

Dr. Andrew Lo, PhD, Charles E. and Susan T. Harris Professor of Finance, MIT Sloan School of Management

Dr. Andrew Lo, PhD, Charles E. and Susan T. Harris Professor of Finance; Director, Laboratory for Financial Engineering, MIT Sloan School of Management. Prior to MIT Sloan, he taught at the University of Pennsylvania Wharton School as the W.P. Carey Assistant Professor of Finance from 1984 to 1987, and as the W.P. Carey Associate Professor of Finance from 1987 to 1988. A former governor of the Boston Stock Exchange, he is currently a Research Associate of the National Bureau of Economic Research; a member of the OFR Financial Research Advisory Committee, the New York Federal Reserve Board’s Financial Advisory Roundtable, and FINRA’s Economic Advisory Committee.
The Global Health Impact Forum:

Ms. Ghislaine Maxwell
Founder and CEO, The TerraMar Project

Ms. Ghislaine Maxwell, Founder and CEO, The TerraMar Project (TM), a web-based non-profit organized to protect the Oceans by empowering a global community of ocean citizens. In addition to promoting awareness, responsibility, and transparency on the high seas, TM is collaborating with countries and other stakeholders to secure healthy oceans through the 2015 United Nations Sustainable Development Goals. TM has created a pledge for supporters to show the United Nations their commitment to sustainable oceans management.

Ms. Maxwell holds a B.A. - M.A. from Oxford University. She is a private helicopter pilot and an Emergency Medical Technician and a qualified ROV and Deepworker submarine pilot.

Vincent W. Li, M.D., M.B.A.
Chief Operating Officer and Scientific Director of the Angiogenesis Foundation

Vincent W. Li M.D., M.B.A.; COO, Scientific Director, and Co-founder of the Angiogenesis Foundation; physician, scientist, social entrepreneur and innovator; honored as HHMI Research Fellow and Harvard Business School Social Enterprise Fellow. He has been involved in the field of angiogenesis since 1998, and has been on the Board since its inception in 1994. Vince conducted his bachelor's thesis with Harvard Professor Howard Green, a pioneer of epidermal and fibroblast biology, and performed his doctoral dissertation on growth factors and tumor angiogenesis as a Howard Hughes Medical Institute Fellow in the research laboratory of angiogenesis pioneer Dr. Judah Folkman. He currently serves as Medical Director of the Angiogenesis and Wound Healing Center in the Department of Dermatology at the Brigham & Women's Hospital, and Harvard Medical School. His honors include the Paul Dudley White Award, the MIT-Japan Science and Technology Prize, First Place Award in the Scientific and Clinical poster competition at the American Academy of Dermatology annual meeting, and the highest recognition (Daland Award) from the New England Cancer Society.

Dr. Muzibul Khan
Corporate and Technology Planning,
Kyocera Communications, Inc.

Dr. Muzibul Khan joined Kyocera Communications, Inc. (KCI), a subsidiary of the global Kyocera Group focused on cellular and mobile devices, in 2013. He is responsible for Corporate and Technology Planning functions, charting the evolution of the business plan and technology portfolio for KCI, which finished 2013 as the fourth-ranked cell-phone manufacturer in the U.S. market. Before joining Kyocera, Dr. Khan served in senior leadership roles in the global telecommunications industry, including Chief Technology Officer (CTO) for Huawei Devices USA, head of Research & Development for Nokia CDMA terminals, Vice President of Product Management & Engineering for the wireless terminals division of Samsung Telecommunications America, and Technical Manager for Systems Engineering, Standards & Regulatory Compliance at Lucent Technologies. Dr. Khan obtained his doctorate degree from Concordia University and began his career as an associate professor of electrical engineering at Lakehead University, Canada. He has authored more than 30 technical publications and received five patents with several patents pending.
Gala Dinner and Receptions

**Gala Dinner:** United Nations, Delegates Dining Room

**Evening Cocktail Reception and Gala Dinner:**
- 6:30 pm: Cocktail reception and Gala Dinner
- ‘Stories Behind the Music’ - special performance by 2014 Rock and Roll Hall of Fame Inductee John Oates

**Tribute Reception:** United Nations, Delegates Dining Room
- 6:30 pm: Cavendish Tribute Reception
- Special performance by Jihae; New York City-based singer/composer/multimedia artist based in New York City. Trace Magazine declared her “A creative genius.” Jihae’s upcoming album, Illusion of You, featuring a co-write with legendary Leonard Cohen and Dave Stewart, is due out Summer 2014. Jihae is also involved in a range of socially responsible projects, most recently including Simon Says Sing For Peace.

**Cavendish Awards Reception:** Rockefeller University, Benjamin and Irma G. Weiss Building, Weiss Cafe
- 6:30 pm: Cavendish Awards Reception & Family Office Panel

**Family Office Panel:** What makes a grant great? Family office insight to grant requests that family offices and their foundations want to fund
Chaired by **Mr. Gregory C. Simon,** Chief Executive Officer Poliwogg; Mr. Simon has held senior positions in both houses of Congress and the White House and led FasterCures/The Center for Accelerating Medical Solutions - the national patient advocacy nonprofit
**Steve Shaya, M.D.** of family office owned J&B Medical
**Ms. Kay Koplovitz,** Co-founder Springboard Enterprises and Founder USA Network
**Mr. Zac Russell,** Trustee Russell Family Foundation
**Ms. Ghislaine Maxwell,** Founder The TerraMar Project
**Ms. Irene Pritzker*,** President, IDP Foundation
### Program Summary

**Monday, May 5th: Global Health Impact Forum and Gala Dinner, United Nations General Assembly Hall**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30 AM</td>
<td>UN Registration</td>
</tr>
</tbody>
</table>
| 10:00 AM | Welcoming Remarks  
Mr. Amir Dossal, Chairman, Global Partnerships Forum  
Mr. Thomas Gass, Assistant Secretary-General for Policy Coordination and Inter-Agency Affairs, UN DESA  
Dr. Roland Rich, Executive Director, United Nations Office for Partnerships |
|       | Opening Keynotes  
Ambassador Gyan Chandra Acharya, High Representative for the Least Developed Countries, Landlocked Developing Countries and Small Island Developing States  
His Excellency Dr Hamadoun Touré, Secretary-General of the International Telecommunication Union  
Saralyn Mark, MD, a world renowned leader in women’s health, is an endocrinologist, geriatrician and women’s health specialist. She was the first Senior Medical Advisor to the Office on Women’s Health within the Department of Health and Human Services |
### Panel I: Impact investments and philanthropy that changes the world - how to identify compelling, pro-social investment and philanthropy opportunities:

**Chaired by Mr. Peter Samuelson**, Chairman, Co-Founder and President, The Starlight Children’s Foundation: Mr. Samuelson is an accomplished film producer and serial pro-social entrepreneur. In 1999 his strong passion for children’s advocacy led him to co-found First Star, a DC based nonprofit dedicated to improving the lives of America’s abused and neglected children. In 1982, he co-founded the Starlight Children’s Foundation—an international charity dedicated to granting wishes for seriously ill children. In 1990 he founded with Steven Spielberg and General Norman Schwarzkopf Starbright World, an online social network to educate, encourage and empower children to cope with the medical, emotional and social challenges of their illness. In 2006, Mr. Samuelson founded EDAR, “Everyone Deserves A Roof” to develop and widely distribute through established service agencies a mobile single-user homeless shelter on wheels.

**Ms. Kay Koplovitz**, Co-founder Springboard Enterprises and Founder USA Network. Ms. Koplovitz co-created Springboard Enterprises, a national organization that fosters venture capital investments in women-led high growth companies. She also co-founded Boldcap Ventures, a venture capital fund backed exclusively by leading women executives.

**Mr. Josh Cohen**, Co-Founder, Managing Director, City Light Capital, Co-Founder, Managing Director, City Light Capital, investing in companies tackling society’s toughest challenges; a firm that he co-founded in 2004. He is currently on the Boards of LicenseStream and City Light Carbon and is an Observer to the Boards of 2Tor and ShotSpotter. He was formerly an Observer to the Board of Arxceo. Mr. Cohen had previous venture capital experience working with a family office in St. Louis and the SV Group.

**Ms. Liesel Pritzker Simmons**, Social entrepreneur, co-founder, Blue Haven Initiative, a family office action tank that focuses on how a family can impact the world by investing different kinds of capital and communicating that story to inspire others.

**Mr. Gregory C. Simon**, Chief Executive Officer Poliwogg; Mr. Simon has held senior positions in both houses of Congress and the White House, been a senior executive at Pfizer and led FasterCures/The Center for Accelerating Medical Solutions – the national patient advocacy nonprofit.

**Mr. Brian Trelstad**, Managing Director, Bridges Ventures; a specialist fund manager, dedicated to using an impact-driven investment approach to create superior returns for both investors and society at-large. Brian has over 10 years of impact investing experience, having served until 2012 as the Chief Investment Officer of Acumen Fund, where he oversaw investments into companies that were delivering health, water, energy, and agriculture services to economic base of the pyramid in South Asia and Sub-Saharan Africa.

---

**Monday, May 5th: Global Health Impact Forum and Gala Dinner, United Nations General Assembly Hall**

**10:45 AM Panel I:**

- Impact investments and philanthropy that changes the world - how to identify compelling, pro-social investment and philanthropy opportunities:
  - **Chaired by Mr. Peter Samuelson**, Chairman, Co-Founder and President, The Starlight Children’s Foundation: Mr. Samuelson is an accomplished film producer and serial pro-social entrepreneur. In 1999 his strong passion for children’s advocacy led him to co-found First Star, a DC based nonprofit dedicated to improving the lives of America’s abused and neglected children. In 1982, he co-founded the Starlight Children’s Foundation—an international charity dedicated to granting wishes for seriously ill children. In 1990 he founded with Steven Spielberg and General Norman Schwarzkopf Starbright World, an online social network to educate, encourage and empower children to cope with the medical, emotional and social challenges of their illness. In 2006, Mr. Samuelson founded EDAR, “Everyone Deserves A Roof” to develop and widely distribute through established service agencies a mobile single-user homeless shelter on wheels.
  - **Ms. Kay Koplovitz**, Co-founder Springboard Enterprises and Founder USA Network. Ms. Koplovitz co-created Springboard Enterprises, a national organization that fosters venture capital investments in women-led high growth companies. She also co-founded Boldcap Ventures, a venture capital fund backed exclusively by leading women executives.
  - **Mr. Josh Cohen**, Co-Founder, Managing Director, City Light Capital, Co-Founder, Managing Director, City Light Capital, investing in companies tackling society’s toughest challenges; a firm that he co-founded in 2004. He is currently on the Boards of LicenseStream and City Light Carbon and is an Observer to the Boards of 2Tor and ShotSpotter. He was formerly an Observer to the Board of Arxceo. Mr. Cohen had previous venture capital experience working with a family office in St. Louis and the SV Group.
  - **Ms. Liesel Pritzker Simmons**, Social entrepreneur, co-founder, Blue Haven Initiative, a family office action tank that focuses on how a family can impact the world by investing different kinds of capital and communicating that story to inspire others.
  - **Mr. Gregory C. Simon**, Chief Executive Officer Poliwogg; Mr. Simon has held senior positions in both houses of Congress and the White House, been a senior executive at Pfizer and led FasterCures/The Center for Accelerating Medical Solutions – the national patient advocacy nonprofit.
  - **Mr. Brian Trelstad**, Managing Director, Bridges Ventures; a specialist fund manager, dedicated to using an impact-driven investment approach to create superior returns for both investors and society at-large. Brian has over 10 years of impact investing experience, having served until 2012 as the Chief Investment Officer of Acumen Fund, where he oversaw investments into companies that were delivering health, water, energy, and agriculture services to economic base of the pyramid in South Asia and Sub-Saharan Africa.
12:00 Noon  |  Panel II: Britain's best kept secret; opportunities to accelerate innovation with the National Health Service (NHS)

**Chaired by Professor Freddie Hamdy**, Head of the Nuffield Department of Surgery, Nuffield Professor of Surgery, Professor of Urology and Honorary Consultant Urological Surgeon at the Oxford Radcliffe Hospitals and Fellow of Balliol College. He has spent the past 10 years as founding Chair of Urology and was Director of the Division of Clinical Sciences, then Head of Oncology at the University of Sheffield.

**Lord Darzi of Denham**, Chairman of Departments of Surgery at Imperial College London Professor Darzi holds the Paul Hamlyn Chair of Surgery at Imperial College London, the Royal Marsden Hospital and the Institute of Cancer Research. He is Director of the Institute of Global Health Innovation at Imperial College London and an Honorary Consultant Surgeon at Imperial College Hospital NHS Trust.

**Mr. Miles Ayling**, Director of Innovation, NHS England & Chair of the NHS Innovation Challenge Prizes Expert Panel. Whilst working for the Department of Health and NHS England, Director of Innovation, Mr. Ayling has been responsible for a number of significant healthcare reform programs including the introduction of legislation on care trusts, delivery of commissioning a patient led NHS and the reconfiguration of services in Primary Care Trusts.

**Ms. Kate Bingham**, Ms. Kate Bingham, Managing Partner, SV Life Sciences, London. The SVLS team manages five private venture capital funds with approximately $1.9 billion of capital under management. The firm employs a diversified strategy within life sciences in order to selectively capitalize on an expanding opportunity in biotech, medical devices and health-care services.

**Sir Andrew Cash**, Chief Executive, Sheffield Trust, founding Chair of the Foundation Trust Network (FTN) and previously served as Director General, Department of Health, England and co-chair of the Department of Health/Ministry of Defence Partnership Board. He is a visiting Professor in Leadership and Development at the Universities of Sheffield and York.

**Sir Jonathan Michael**, Chief Executive Oxford University Hospitals NHS Trust and Trustee of the King's Fund. His previous roles include Managing Director of BT Health, Chief Executive of Guys and St Thomas's Hospitals NHS Foundation Trust and Chief Executive of University Hospitals Birmingham NHS Trust.

Continued
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:15 PM</td>
<td>Luncheon: United Nations Delegates Dining Room</td>
</tr>
<tr>
<td></td>
<td><strong>Keynote Speaker:</strong>  <strong>Professor the Lord Darzi of Denham</strong>, Professor Darzi holds the Paul Hamlyn Chair of Surgery at Imperial College London, the Royal Marsden Hospital and the Institute of Cancer Research. He is Director of the Institute of Global Health Innovation at Imperial College London and an Honorary Consultant Surgeon at Imperial College Hospital NHS Trust. He was knighted for his services in medicine and surgery in 2002. In 2007, he was introduced to the United Kingdom's House of Lords as Professor the Lord Darzi of Denham and appointed Parliamentary Under-Secretary of State at the Department of Health. Professor Darzi served as the United Kingdom's Global Ambassador for Health and Life Sciences. In 2013 he hosted the World Innovation Summit for Health in Doha, Qatar, under the Patronage of Her Highness Sheikha Moza bint Nasser al Missned and Qatar Foundation.</td>
</tr>
<tr>
<td></td>
<td><strong>Groundbreaking discoveries and innovations from Great Britain:</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Mr. William Allan</strong>, CEO Vascular Flow Technologies</td>
</tr>
<tr>
<td></td>
<td><strong>Mr. Ian Paling</strong>, CEO CellCoTec</td>
</tr>
</tbody>
</table>

Continued
### Panel III: How to identify innovations with the potential for transformational impact on disease outcomes and ensure successful integration into medical practice

Respected leaders from the world of private-equity and highly accomplished entrepreneurs will share secrets to identifying innovations with the potential for transformational impact and making sure they get integrated into medical practice.

- **Mr. Alexander Saint-Amand**, President and CEO of GLG, the world's largest membership for professional learning and expertise. He is a founding member of the company and previously served as its Chief Operating Officer. During his tenure and under his leadership, GLG has grown from a small start-up to one of New York City's most successful venture-backed companies, having facilitated over 1.5 million teaching and learning projects, and now with over 20 offices in 12 countries.

- **Mr. Aly Sheezar Jeddy**, Partner, HealthCare & Institutional Coverage, The Abraaj Group. Mr. Jeddy plays Group-wide investment and firm management roles as well as supporting the firm's investor relations activities in the United States. Mr Jeddy joined Abraaj after twenty years at McKinsey & Company where he was a Senior Partner based in New York and Head of the Private Equity and Principal Investing Practice in the Americas.

- **Mr. Steve McLean**, Arsenal Capital Partners; a progressive private equity firm with $1.65 billion under management that facilitates transformational growth and change through a collaborative approach. Prior to joining Arsenal in 2010, Mr. McLean was a Managing Director at Courtagen Capital Group and its predecessor companies where he invested in healthcare companies.

- **Mr. Adair Newhall**, Principal, Domain Associates; Domain was one of the first venture capital firms to exclusively invest in the life sciences sector. Domain has been involved in the formation of more than 250 companies, with more than $2.7 billion in capital raised to-date.

- **Mr. Stanton (Stan) J. Rowe**, Chief Scientific Officer & Corporate Vice President, Edwards Lifesciences and also serves as Corporate Vice President, Advanced Technology. He joined the company in 2004 when Edwards acquired Percutaneous Valve Technology, of which he was president and CEO and helped to found in 1999. Previously, Rowe was Corporate Vice President of Business Development and Strategic Planning for Datascope and was Vice President of Business Development for Johnson & Johnson's Interventional Systems Division (JJIS), responsible for the company's coronary stent development efforts.

- **Andrew Schiff, M.D.**, Managing Director, Aisling Capital a leading investment firm focused on novel approaches toward the diagnosis, prevention, and treatment of life-threatening illnesses. Prior to joining Aisling, Dr. Schiff practiced internal medicine at The New York Presbyterian Hospital where he maintains his position as a Clinical Assistant Professor of Medicine.

---

**Monday, May 5th: Global Health Impact Forum and Gala Dinner, United Nations General Assembly Hall**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:45 PM</td>
<td>Panel III: How to identify innovations with the potential for transformational impact on disease outcomes and ensure successful integration into medical practice.</td>
</tr>
</tbody>
</table>

Continued...
# Monday, May 5th: Global Health Impact Forum and Gala Dinner, United Nations General Assembly Hall

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 4:00 PM      | **Groundbreaking discoveries and innovations:** Recent discoveries in Neurodegenerative Diseases revealed; potential for transformational impact on disease prevention, diagnosis and treatment; Chairman, Dr. Jonathan Sackier  
**Dr. R.J Tesi**, CEO FPRT Bio  
**Dr. Alan Snow**, Chairman and CEO ProteoTech  
**Mr. Larry Tiffany**, CEO DioGenix |
| 4:45 PM      | **Groundbreaking discoveries and innovations:** Recent discoveries in Cancer revealed; potential for transformational impact on disease prevention, diagnosis and treatment; Chairman, Dr. Jonathan Sackier  
**Dr. Graham Kelly**, CEO Novogen  
**Mr. David Kalergis**, CEO Diffusion |
| 5:15 PM      | **Mr. Tony Kuhn**, CEO The Load Zero Foundation; Viral Load Testing for the Developing World |
| 5:30 PM      | **Panel IV: “Be He@lthy, Be Mobile”**  
*Chaired by Mr. Gary Fowlie*, Head, ITU Liaison Office to the UN. Global health policy leaders and internationally respected mobile technology and broadband innovators will provide insights to the transformational impact of telemedicine, mobile health and broadband on health access and outcome  
**Jacob Kumaresan**, Head of WHO NYC office  
**Dr Fiona Adshead**, Director of Wellbeing and Public Health, Bupa  
**Leslie Martinkovics**, Director, International Public Policy & Regulatory Affairs, Verizon Communications, Inc.  
**Erik Augustson**, Program Director, National Cancer Institute, Tobacco Control Research Branch, Behavioral Research Program |
| 6:30 PM      | **Gala Dinner:** United Nations Delegates Dining Room  
**Special performance by Mr. John Oates**, 2014 Rock and Roll Hall of Fame Inductee  
**Keynote Speaker:** Mehmood Khan M.D. Executive Vice President and Chief Scientific Officer, Global Research & Development at PepsiCo. As chief scientific officer, Mehmood leads company-wide research and development (R&D); recruits highly regarded clinical scientists, global health leaders and medical experts; launches research projects with leading universities; and opens advanced R&D facilities. Prior to joining PepsiCo, Mehmood was as a faculty member at the Mayo Clinic and Mayo Medical School in Rochester, Minn., serving as director of the Diabetes, Endocrine and Nutritional Trials Unit in the endocrinology division. He also spent nine years leading programs in diabetes, endocrinology, metabolism and nutrition for the Hennepin County Medical Center in Minneapolis |

* Invited
## Tuesday, May 6th: Global Health Impact Forum and Tribute Reception, United Nations ECOSOC Chamber

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 AM</td>
<td>UN Registration</td>
</tr>
<tr>
<td>10:00 AM</td>
<td><strong>Welcoming Remarks</strong></td>
</tr>
<tr>
<td></td>
<td>Mr. Gary Fowlie, Head, ITU Liaison Office to the UN</td>
</tr>
<tr>
<td></td>
<td><strong>Opening Keynote</strong></td>
</tr>
<tr>
<td></td>
<td>Scott Parazynski, Astronaut, Everest Climber, Physician, and Telemedicine Champion</td>
</tr>
<tr>
<td></td>
<td>Mr. John H. Friedman, Founding and Managing Partner, Easton Capital, a leading private equity firm focused only on those opportunities that offer services or products that can materially improve the healthcare people receive or reduce its cost</td>
</tr>
<tr>
<td>10:30 AM</td>
<td>Panel I: The transformational impact of telemedicine, broadband and mobile health on health access and outcomes; Global health policy leaders and internationally respected mobile technology and broadband innovators will provide insights to the transformational impact of telemedicine, mobile health and broadband on health access and outcomes</td>
</tr>
<tr>
<td></td>
<td>Mr. Yasuhiro Oishi, President, Kyocera Communications Inc.</td>
</tr>
<tr>
<td></td>
<td>Dr. Muzibul Khan, Corporate and Technology Planning, Kyocera Communications, Inc.</td>
</tr>
<tr>
<td></td>
<td>Steve Shaya M.D. of family office owned J&amp;B Medical and member of 'Pietas', the global nonprofit dedicated to providing telemedicine solutions for rural and indigenous communities</td>
</tr>
</tbody>
</table>

Continued
<table>
<thead>
<tr>
<th>Time</th>
<th>Item</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:15 AM</td>
<td><strong>Panel II: How to win the battle against diabetes and obesity:</strong> Accomplished scientists, philanthropists, health policy experts and senior executives from innovative private-sector companies will reveal specific initiatives that are helping to win the battle against diabetes and obesity and explore opportunities to bring about lasting change. <strong>Chaired by Mr. David Jones, Jr.</strong> Director of Humana, The Humana Foundation, Inc., Board member of the National Committee on U.S.-China Relations and Chairman of Chrysalis Ventures. Mr. Jones is a well-respected voice in healthcare business, innovation and education. Mr. Jones brings a strong and well-rounded background in business, law and banking to his work at Chrysalis Ventures, which he founded in 1993. David is active in civic and charitable affairs on both national and local levels. <strong>Mehmood Khan, M.D.</strong> Executive Vice President and Chief Scientific Officer, Global Research &amp; Development at PepsiCo. As chief scientific officer, Mehmood leads company-wide research and development (R&amp;D); recruits highly regarded clinical scientists, global health leaders and medical experts; launches research projects with leading universities; and opens advanced R&amp;D facilities. <strong>Mr. Paul LaViolette,</strong> Managing Partner SV Life Sciences and previously Chief Operating Officer at Boston Scientific Corporation (BSC), also served at BSC as COO, Group President, President-Cardiology and President-International. During his 15 years at BSC, he served as COO, Group President, President-Cardiology and President-International. Mr. LaViolette previously held marketing and general management positions at CR Bard, and various marketing roles at Kendall (Covidien). <strong>Saralyn Mark, M.D.</strong> Saralyn Mark, MD, a world renowned leader in women’s health, is an endocrinologist, geriatrician and women’s health specialist. She was the first Senior Medical Advisor to the Office on Women’s Health within the Department of Health and Human Services. <strong>Dr. Nandan Padukone,</strong> Ph.D., MBA, Vice President Office of Commercialization &amp; Ventures, (OCV) Joslin Diabetes Institute of Harvard Medical School. Dr. Padukone helped launch the OCV as a business center of Joslin Diabetes Center to create strategic relationships with industry and leverage Joslin’s world-leading expertise in diabetes-directed research and clinical care. <strong>Maj. Gen. Gale Pollock,</strong> Former Deputy Surgeon General of the United States Army, and served as Acting Surgeon General of the Army as well as the 22nd Chief of the Army Nurse Corps. The Acting Surgeon General position made Maj. General Pollock one of the few women in the US to run a Fortune 50 sized organization with a $9.7B budget. <strong>Dr. Robert E. Ratner</strong> is Chief Scientific &amp; Medical Officer for the American Diabetes Association, the nation’s largest voluntary health organization leading the fight to Stop Diabetes®. Dr. Ratner provides leadership and oversight of scientific and medical activities including research, clinical affairs, program recognition and certification, medical information and professional education.</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
</tr>
<tr>
<td>------</td>
<td>-------</td>
</tr>
</tbody>
</table>
| 12:30 PM | Luncheon: United Nations Delegates Dining Room  
**Keynote Speaker:** Mr. Peter Samuelson Chairman, Co-Founder and President, The Starlight Children’s Foundation (co-founded by Peter Samuelson and Steven Spielberg)  
**Groundbreaking discoveries and innovations in Mobile Health and Technology:**  
Mr. Alan Portela, CEO Airstrip Technologies  
Ms. Abigail Cohen and Mr. Andrew Brimer, Co-Founder and Co-CEO, Sparo Labs |
| 2:00 PM | **Groundbreaking discoveries and innovations:** Recent discoveries in **Cancer** revealed; potential impact on disease prevention, diagnosis and treatment; Chairman, Dr. Scott Parazynski  
Mr. Andrew Krouse, CEO Tau Therapeutics  
Mr. Robert Fallon, CEO Phosplatin Therapeutics  
Mr. David McCaleb, CEO Susavion Biosciences  
Dr. George Thomas, PhD. CEO Marsala Biotech  
Dr. Charles Magness, CEO Kineta |
| 3:15 PM | **Groundbreaking discoveries and innovations:** Recent discoveries in **Mobile Health & Technology** revealed; potential impact on disease prevention, diagnosis and treatment; Chairman, Dr. Scott Parazynski  
Mr. Allan Binks, CEO SHI Global Innovative Health Solutions  
Mr. John Murphy, CEO Virtual Incision  
Mr. James Carroll, CEO Thor Laser |
| 4:00 PM | **Groundbreaking discoveries and innovations:** Recent discoveries in **Molecular Diagnostics** revealed; potential impact on disease prevention, diagnosis and treatment; Chairman, Dr. Saralyn Mark  
Mr. R. Brian McKernan, CEO Courtagen Life Sciences  
Mr. Guido Baechler, CEO Singulex  
Dr. Jacqueline Barnea, Esq. President & CEO BioIncept  
Dr. Bernhard Sixt, PhD. Chairman and Chief Executive Officer ImmunID |
| 5:00 PM | **Groundbreaking discoveries and innovations:** Recent discoveries in **Cardiovascular disease and Diabetes** revealed; potential impact on disease prevention, diagnosis and treatment; Chairman, Saralyn Mark, M.D.  
Mr. Douglas Baum, CEO Xeris Pharmaceuticals  
Mr. David Thrower, CEO Asante Solutions |
**Tuesday, May 6th: Global Health Impact Forum and Tribute Reception, United Nations ECOSOC Chamber**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>5:30 PM</td>
<td><strong>Groundbreaking discoveries and innovations panel discussions:</strong> Recent discoveries in <strong>Infectious Diseases</strong> revealed; potential impact on disease prevention, diagnosis and treatment; Chairman, <strong>Dr. Jonathan Sackier</strong>&lt;br&gt;Dr. Michel Bazinet, M.D. CEO Replicor&lt;br&gt;Mr. John Reisky de Dubnic, CEO Cavidi&lt;br&gt;Mr. Michael Smith, CFO Safe Eggs&lt;br&gt;Dr. Mark Benedyk, CEO Telephus Medical&lt;br&gt;Mr. Clifford Stocks, CEO Theraclone Sciences</td>
</tr>
<tr>
<td>6:30 PM</td>
<td><strong>Tribute Reception:</strong> United Nations Delegate Dining Room&lt;br&gt;<strong>Special performance by Jihae:</strong> New York City-based singer/composer/multimedia artist</td>
</tr>
</tbody>
</table>

**Continued**
**Wednesday, May 7th: Global Health Impact Forum and Reception, Rockefeller University, Caspary Auditorium**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 AM</td>
<td>Registration – Rockefeller University, Caspary Auditorium, Coffee and Refreshments</td>
</tr>
<tr>
<td>8:45 AM</td>
<td>Welcoming Remarks&lt;br&gt;Paul Reverdy and Christine Odabashian, Robotic Exoskeleton, Princeton University&lt;br&gt;Dr Murali Prahalad, PH. D., CEO Epic Sciences&lt;br&gt;Panel I: Ground-breaking approaches to discovery that are transforming innovation and outcomes: Case-studies reveal the methods that are making a difference&lt;br&gt;The National Institutes of Health Oxford-Cambridge Scholars Program is having an extraordinary impact on the development of the next generation of scientists. The Panel will reveal the ground-breaking methods and impact of this unique program.&lt;br&gt;The Angiogenesis Foundation is the world's first nonprofit organization dedicated to conquering disease using a new approach based on angiogenesis, the growth of new capillary blood vessels in the body. The Foundation has developed a unique social enterprise model based on international collaborations with leading medical academic centers, biopharmaceutical companies, and government agencies, including the National Institutes of Health, National Cancer Institute, and the Food and Drug Administration&lt;br&gt;William W. Li M.D.; President, Medical Director, and Co-founder of the Angiogenesis Foundation; Will trained in the lab of Dr. Judah Folkman, pioneer of the angiogenesis field, and has been actively engaged in angiogenesis research and clinical development for 22 years&lt;br&gt;Vincent W. Li M.D., M.B.A.; COO, Scientific Director, and Co-founder of the Angiogenesis Foundation; physician, scientist, social entrepreneur and innovator; honored as HHMI Research Fellow and Harvard Business School Social Enterprise Fellow&lt;br&gt;Michael Lenardo M.D.; Co-founder of the National Institutes of Health Oxford-Cambridge Scholars Program; Section Chief at Laboratory of Immunology, NIAID, NIH&lt;br&gt;Richard Siegel MD PhD, Co-founder of the National Institutes of Health Oxford-Cambridge Scholars Program; Clinical Director of the National Institutes of Arthritis And Musculoskeletal Diseases&lt;br&gt;Ms. Arianne Richard, an NIH-Cambridge Scholar</td>
</tr>
<tr>
<td>10:00 AM</td>
<td>Mr. David Auerbach, CEO Sanergy: In the slums of Nairobi, millions of inhabitants rely on makeshift sanitation facilities. The World Health Organization estimates that 2.6 billion people worldwide lack access to hygienic toilets, causing the spread of disease. David Auerbach thinks the private sector can help.</td>
</tr>
</tbody>
</table>

Continued
Panel II: New York Academy of Sciences hosted panel, “Innovative Models of Funding for High Risk Disease”

Chaired by Mr. Ellis Rubinstein, President and Chief Executive Officer, The New York Academy of Sciences. The New York Academy of Sciences CEO, Ellis Rubinstein, and a world class panel of accomplished experts will provide insights into how to leverage investments in high risk areas of disease research such as neurodegenerative diseases and specifically Alzheimer’s. While research in disease prevention, treatment and drug development can be high risk, under the right circumstances, philanthropists will support such work. We have been honored to organize a panel addressing the newest thinking in social investment for high risk research.

Mr. Labeeb Abboud, Senior Vice President Business Development and Strategy & General Counsel, IAVI; Fund Manager, Global Health. Mr. Abboud is responsible for the legal, intellectual property and risk-management considerations associated with IAVI’s operations and partnerships. He also oversees the organization’s business development efforts. Prior to joining IAVI, Mr. Abboud served as general counsel to Atriax, a London-based electronic marketplace for foreign exchange products and as group counsel to American Express Bank, Ltd. Mr. Abboud is currently vice chair of the Rainforest Alliance, a director of Shackleton Schools and NEPCon and a member of the Council on Foreign Relations.

Dr. Andrew Lo, PhD, Charles E. and Susan T. Harris Professor of Finance; Director, Laboratory for Financial Engineering, MIT Sloan School of Management. Prior to MIT Sloan, he taught at the University of Pennsylvania Wharton School as the W.P. Carey Assistant Professor of Finance from 1984 to 1987, and as the W.P. Carey Associate Professor of Finance from 1987 to 1988. A former governor of the Boston Stock Exchange, he is currently a Research Associate of the National Bureau of Economic Research; a member of the OFR Financial Research Advisory Committee, the New York Federal Reserve Board’s Financial Advisory Roundtable, and FINRA’s Economic Advisory Committee.

Mr. Pablo Legorreta, Founder and Chief Executive Officer, Royalty Pharma. Mr. Legorreta founded Royalty Pharma in 1996, after creating and managing two “proof of principle” investment vehicles in 1993 and 1994 that invested in royalty interests in two leading biotechnology products. Prior to founding these investment vehicles, Mr. Legorreta spent ten years at Lazard Frères where he provided cross-border merger and acquisition and corporate finance advisory services to US and European corporations.

Dr. Sam Hall, PhD, Associate, Apple Tree Partners. Dr. Hall has over a decade of experience in the life sciences across roles as a private equity investor, investment banker and basic scientist. Prior to joining Apple Tree in 2013, he was a researcher at the University of Cambridge in the UK, where his work focused on novel therapeutic strategies for autoimmune diseases. Previously Dr. Hall was a member of the investment team at Symphony Capital, a private equity firm dedicated to investments in biopharmaceutical development.

Ms. Melissa Stevens, Deputy Executive Director, FasterCures a nonprofit think tank and center of the Milken Institute that works across sectors to improve the effectiveness and efficiency of the medical research enterprise, and accelerate the discovery and development of new treatments for deadly and debilitating diseases. Ms. Stevens manages planning and implementation of FasterCures programs and directs the organization’s medical philanthropy efforts including the Philanthropy Advisory Service.
**Wednesday, May 7th: Global Health Impact Forum and Reception, Rockefeller University, Caspary Auditorium**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 11:30 AM | **Groundbreaking discoveries and innovations panel discussions:** Recent discoveries in *Neurodegenerative Diseases* revealed; potential impact on disease prevention, diagnosis and treatment; Chairman, **Dr. Jonathan Sackier**  
**Mr. Stephen L. Hurst**, CEO Savant HWP  
**Mr. Gerald Commisiong**, CEO Amarantus BioScience  
**Ms. Marie Wesselhoft**, CEO MSDx  
**Professor Malcolm Horne**, Managing Director Global Kinetics |
| 12:45 PM | **Luncheon:** Rockefeller University                                   |
| 2:00 PM  | **Groundbreaking discoveries and innovations panel discussions:** Recent discoveries in *Enabling Platform Technologies* revealed; potential impact on disease prevention, diagnosis and treatment; Chairman, **Mr. Alex Charlton**  
**Dr. Trevor Castor**, CEO Aphious  
**Dr. Steven Tregay**, Forma Therapeutics  
**Mr. Richard T. Schumacher**, CEO Pressure BioScience |
| 2:50 PM  | **Groundbreaking discoveries and innovations panel discussions:** Recent discoveries in *Cancer* revealed; potential impact on disease prevention, diagnosis and treatment; Chairman, **Mr. Alex Charlton**  
**Mr. George Colberg, M.D.** CEO Kalos Therapeutics  
**Dr. George Thomas, PhD.** CEO Marsala Biotech |

Continued
### Wednesday, May 7th: Global Health Impact Forum and Reception, Rockefeller University, Caspary Auditorium

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Panel Discussions</th>
<th>Chairmen</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:25 PM</td>
<td>Groundbreaking discoveries and innovations panel discussions: Recent discoveries in Molecular Diagnostics revealed; potential impact on disease prevention, diagnosis and treatment</td>
<td>Chairman, Dr. Jonathan Sackier</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mr. David Weaver, CEO Blaze Medical Devices</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dr. Eytan R. Barnea, MD FACOG, S.I.E.P. Chairman The Society for the Investigation of Early Pregnancy</td>
<td></td>
</tr>
<tr>
<td>4:00 PM</td>
<td>Groundbreaking discoveries and innovations panel discussions: Recent Discoveries in Infectious Diseases revealed; potential impact on disease prevention, diagnosis and treatment</td>
<td>Chairman, Dr. Jonathan Sackier</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dr. David Huizenga, CEO Klaren Technologies</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mr. Kenneth Kelley, CEO PaxVax</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dr. Brett Baker, CEO Microbion Corporation</td>
<td></td>
</tr>
<tr>
<td>6:30 PM</td>
<td>Cavendish Awards Reception: Rockefeller University, Benjamin and Irma G. Weiss Building</td>
<td>Family Office Panel: &quot;What makes a grant great or philanthropic gift? Family office insight to grant and philanthropy requests that family offices and their foundations want to fund. Family offices will reveal their favorite grants and philanthropic gifts, what made them great and provide insights into what makes a grant application compelling.&quot;</td>
<td>Chaired by Mr. Gregory C. Simon, Chief Executive Officer Poliwogg; Mr. Simon has held senior positions in both houses of Congress and the White House and led FasterCures/The Center for Accelerating Medical Solutions, the national patient advocacy nonprofit</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mr. Jesse H. Ausubel, Director of the Program for the Human Environment of The Rockefeller University</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ms. Kedge Martin, Co-founder of Longbow, Ms. Martin a founder member of TRH Duke and Duchess of Cambridge and Prince Harry's Charities Forum, and formerly CEO of Sentebale, Prince Harry's charity for African orphans</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ms. Ghislaine Maxwell, Founder The TerraMar Project</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ms. Irene Pritzker, President, IDP Foundation, dedicated to developing programs in education that are sustainable and move away from aid dependent model</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mr. Zac Russell, Trustee Russell Family Foundation</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Steve Shaya, M.D., Dr. Shaya's family founded and own J&amp;B Medical, he is also a member of 'Pietas', the global nonprofit dedicated to providing telemedicine solutions for rural and indigenous communities</td>
<td></td>
</tr>
</tbody>
</table>